EyeGate Pharma Announces That EGP-437 Improved Signs and Symptoms of Dry Eye Syndrome in a Phase II Study

June 10, 2009

EyeGate Pharma announced last week that EGP-437, a corticosteroid solution administered by a non-invasive ocular drug delivery system, improved signs and symptoms in patients with dry eye syndrome (DES) in a Phase II study.

The Phase II single-center, randomized (105 patients), double-masked, placebo-controlled patient study evaluated the safety and efficacy of a corticosteroid solution (EGP-437) administered by the EyeGate® II Delivery System (at two dose levels) twice over a three-week period.

In the top-level analysis, investigators observed that EGP-437 significantly (p < 0.05) improved signs and symptoms of DES during the three-week environmental component, which included three CAE exposures and two doses. EGP-437 also improved signs and symptoms when studied as a treatment and preventative in conjunction with the CAE.

Read the full release.




Jump down to form below to submit your own comments

Trackback URL

Have insights to contribute? Please submit your comment below